Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + gemcitabine + cisplatin + immune checkpoint inhibitor
- Development stage
- Unknown
- Lead developer
- Zhongshan Hospital, Fudan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen consists of chidamide, gemcitabine, cisplatin, and an immune checkpoint inhibitor, specifically a PD-1 monoclonal antibody. Chidamide is an oral histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator, potentially enhancing the antitumor activity of chemotherapy and immunotherapy by altering the tumor microenvironment and increasing the expression of tumor-associated antigens. Gemcitabine and cisplatin are standard cytotoxic chemotherapy agents that induce DNA damage and inhibit DNA synthesis. The addition of a PD-1 inhibitor aims to restore T-cell mediated anti-tumor immunity. This quadruple combination is being investigated as a first-line treatment for patients with advanced intrahepatic cholangiocarcinoma (ICC), a type of liver cancer, in a Phase II clinical trial led by Shanghai Zhongshan Hospital.
- Other names
- chidamide + gemcitabine + cisplatin + pd-1 inhibitor
02
Targets
DNAHDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on chidamide + gemcitabine + cisplatin + immune checkpoint inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + gemcitabine + cisplatin + immune checkpoint inhibitor.